PRENATAL DIAGNOSTICS · TRIO WGS

More answers, before birth.

Whole-genome sequencing of the fetus, with comparative parental analysis.

A comprehensive genomic approach to investigating genetic conditions when clinically indicated, in collaboration with the treating clinician and supported by genetic counselling.

An expectant mother and her partner speaking with a doctor.
GENOMICS IN PREGNANCY

When a finding needs more answers.

Prenatal genomic testing can help investigate genetic conditions in selected pregnancies, particularly when fetal anomalies or other findings raise a specific clinical suspicion.

Clinical indication

Test selection starts with clinical findings, history and previous results.

Family context

Comparing fetal and parental data helps interpret the origin of variants.

Genetic counselling

Counselling before and after testing, with a clear discussion of capabilities, limitations and possible outcomes.

THREE GENOMES · ONE CLINICAL QUESTION

Trio WGS: the fetus in its family context.

Analysing the fetus alongside the mother and father helps distinguish inherited and possible de novo findings and assess potential inheritance patterns.

Family comparison in practice

Mother

Genetic information

Father

Genetic information

Fetus

Clinical findings + WGS

Comparative interpretation

Variant origin · inheritance pattern · relevance to the fetal phenotype

A variant’s absence from the parents does not by itself establish that it is pathogenic. Each finding requires clinical and laboratory evaluation.

WHOLE-GENOME SEQUENCING

A broader dataset for focused clinical interpretation.

WGS generates data from coding and non-coding regions of the genome. Analysis focuses on findings that may be relevant to the pregnancy’s clinical indication.

Genes and their wider genomic context

Coding regionsIntronic and other non-coding regions
WES · exome
WGS · genome
Educational schematic, not a coverage measurement. Actual detection depends on the region, data quality and validated methodology.

Small sequence changes

Single-nucleotide variants and small insertions or deletions in assessable regions.

Copy number & structure

Assessment of copy-number changes or structural variants where the relevant analysis has been validated.

Beyond the exons

Assessment of selected non-coding findings when sufficient evidence supports clinical relevance.

FROM INDICATION TO INTERPRETATION

A coordinated pathway with your clinical team.

Testing is planned with the treating clinician and genetics specialists. Fetal sampling is performed by the responsible obstetrician when indicated.

The main steps

01Counselling & indication

Clinical findings, history and informed consent.

02Fetal & parental samples

Fetal DNA and appropriate parental samples.

03Trio WGS & interpretation

Quality assessment and comparative family analysis.

04Results & counselling

Explanation of findings and discussion of next steps.

The fetal sample

DNA from amniotic fluid or chorionic villi, according to the clinical decision and laboratory requirements.

Parental samples

Appropriate samples from both biological parents, following laboratory instructions.

POSSIBLE OUTCOMES

Clear explanations of both possibilities and limits.

Results are always interpreted in relation to the fetal phenotype. Reporting policies and possible uncertainties are discussed before testing.

Clinically significant finding

A finding that may contribute to a genetic diagnosis and counselling for the family.

No diagnostic explanation

A negative result does not exclude every genetic condition or every possible cause of the findings.

Interpretive uncertainty

Some findings may remain uncertain; assessment and reporting follow clinical policy and consent. A variant of uncertain significance does not establish a diagnosis.

INTERNATIONAL SOURCES

International recommendations & clinical evidence

Prenatal genomics requires appropriate case selection, validated laboratory analysis and informed genetic counselling.

INTERNATIONAL RECOMMENDATIONS · 2026

Global recommendations for the use of diagnostic genomic sequencing in the prenatal setting on behalf of the ESHG and ISPD.

Deans ZC et al. · European Journal of Human Genetics · 2026

Joint ESHG and ISPD recommendations on diagnostic genomic sequencing in prenatal care, emphasising clinical indication, counselling and appropriate interpretation.

DOI: 10.1038/s41431-026-02217-4View source ↗
PRIMARY PRENATAL STUDY · 2023

Comprehensive prenatal diagnostics: Exome versus genome sequencing.

Miceikaite I, Fagerberg C, Brasch-Andersen C, et al. · Prenatal Diagnosis · 2023;43(9):1132–1141

A study in selected pregnancies with fetal anomalies examining the diagnostic use of WES and WGS. Its findings do not estimate performance across all pregnancies.

DOI: 10.1002/pd.6402View source ↗
COMMON QUESTIONS

Answers before deciding on testing.

Your clinical team will help you understand which test addresses the specific question in your pregnancy.

Is this the same as NIPT?

No. Trio WGS here refers to diagnostic analysis of fetal DNA from amniotic fluid or chorionic villi when indicated. NIPT is a different screening test performed using maternal blood.

Is it intended for every pregnancy?

Prenatal diagnostic genomics is used after clinical assessment. Suitability depends on findings, family history and previous investigations.

Does it replace every other genetic test?

No. Detection capabilities differ by finding type. The clinical team may recommend complementary or confirmatory tests depending on the indication and validated analysis.

What does a negative result mean?

It means that no diagnostic explanation was identified within the scope and limits of the analysis. It does not guarantee that all genetic or other conditions have been excluded.

The next step starts with a conversation.

The NeoScreen team can explain the test, sample collection and coordination with your clinician.

Talk to our team ↗